Physician profile
Brock Robert Lasure
NPI 1922055532
$1,107.27
in general payments reported to CMS, 2019-2025
18 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.37 · 2020: $30.71 · 2022: $161 · 2023: $222 · 2024: $278 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $227.36 | 2022-2025 | |
| Pfizer INC. | $170.91 | 2022-2025 | |
| Lilly USA, LLC | $126.36 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $124.09 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $55.74 | 2020-2024 | Prolia, Evenity |
| Astellas Pharma US INC | $53.13 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $47.70 | 2023-2025 | |
| Exact Sciences Corporation | $42.00 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $35.26 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $33.34 | 2024-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Sanofi Pasteur INC. | $32.10 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $31.63 | 2025 | Fanapt, Hetlioz |
| Astrazeneca Pharmaceuticals LP | $29.62 | 2024 | |
| Glaxosmithkline, LLC. | $25.20 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.93 | 2024 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $20.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.82 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.93 | 2025 | Ajovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brock Lasure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.